ClinicalTrials.gg
RecruitingNCT06951035BCINETUpdated Jun 5, 2026

Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke

An interventional study of Repetitive transcranial magnetic stimulation (rTMS) in Chonic Stroke Patients With Motor Impairment of Upper Limb, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Institut National de la Santé Et de la Recherche Médicale, France.

Planned enrollment
2nd of 10
50 · median 39
Started
2025
the only one that year
No phase
8 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 13th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Stroke by Institut National de la Santé Et de la Recherche Médicale, France, or all of them as a file.
02

Study summary

Cerebrovascular accidents (strokes) are a major public health issue. Stroke is the 3rd leading cause of death and the leading cause of disability and loss of autonomy. In France, there are currently 130,000 new cases per year, and the aging of the population will lead to an increase in this number over the next few years. Among post-stroke impairments, motor deficit of the upper limb is the most common disability, affecting 73-88% of first-time stroke patients and 55-75% of chronic patients. Associated deficits can complicate rehabilitation management and affect recovery. The clinical profile of patients with motor deficits is therefore varied and complex, requiring an individualized approach. At present, only physiotherapy is recommended, with modest results.

Repeated transcranial magnetic stimulation is a therapy that can improve motor recovery, but currently has a low level of evidence according to the HAS (French Hight Health Authority), notably because of variability in efficacy due to heterogeneity in the clinical profile of patients. Nevertheless, it is still recommended for the recovery of cognitive functions, but also for resistant depression, and could be used to stimulate motor imagery (MI). MI training also has the advantage of stimulating the motor network. Difficult to achieve for a number of patients, the use of rTMS could facilitate this cognitive task and, in particular, provide better access to brain-computer interfaces (BCI). Indeed, among the innovative rehabilitation therapies, BCIs have emerged as the most promising. By translating brain activity during a cognitive task into a command such as electrical muscle stimulation, BCIs would restore the damaged motor network and induce motor recovery. The main obstacle to their widespread use in clinical practice is their lack of reliability, as almost 30% of patients are unable to control them correctly, either because of difficulty in performing the MI task, or because of difficulty in identifying a universal brain signature.

The BCINET project aims to improve the reliability of BCIs in two ways: by improving detection of the motor imagination task using new brain signatures, and through cognitive facilitation using rTMS.

  1. - Using the dynamic communication of different brain areas during the MI task (or functional connectivity), we can identify patient-specific signatures. Studies of functional connectivity in healthy subjects performing an MI task without associated BCI have shown the interest of certain measures such as node degree or clustering coefficient. To find out whether functional connectivity parameters can be used in BCI algorithms, we will evaluate their effectiveness on an initial group of 5 patients to define their performance in discriminating the MI task and to determine their evolution over time in the absence of brain stimulation in stroke patients. Their initial study will also enable us to identify their evolution when TMS stimulation is applied.
  2. - Cerebral magnetic stimulation could facilitate the MI task and enable better BCI rehabilitation for a number of patients. Two studies using either an inhibitory or excitatory stimulation protocol showed an improvement in spectral power signal and better discrimination of the MI task. However, the results were acquired using a single pre- and post-therapy measurement, and did not take into account behavioral variability in the use of BCIs or variability in TMS response according to patient profile. Therefore, in order to identify whether rTMS would improve BCI control, we would perform 9 Single-Case Experimental Design (SCED) studies in multiple baselines on a group of 5 patients according to 3 clinical profiles and 3 rTMS stimulation strategies. SCEDs are suitable experimental models for heterogeneous populations, particularly when the intervention presents some inter-individual variability in efficacy. They have the advantage of being able to demonstrate, on an individual scale, the effectiveness of the intervention on a small group of patients. Replication of the SCED allows us to increase the external validity of the intervention on sub-groups of patients (clinical severity, presence of associated hemineglect) and to study modifications in the interventional strategy (stimulation frequency, stimulation site).
03

Conditions studied

  • Chonic Stroke Patients With Motor Impairment of Upper Limb

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Single Stroke older than 6 months
  • Distal motor deficit of the upper limb (UE-FMA score \< 53) with visible extension of the fingers (Medical Research Council (mRC) score ≥ 2)
  • Right-handed
  • Between 18 and 85 years of age
  • Having given their written consent

Exclusion criteria

Exclusion Criteria:

  • Patient under tutorship or guardianship, under safeguard of justice, deprived of liberty, pregnant or breast feeding women
  • Life-threatening pathologies or compromising follow-up during the study period
  • Trouble of understanding : score below 12/15 in the Boston Diagnostic Aphasia Examination (BDAE) order execution test
  • Fixed spasticity of finger or carpal flexors (mAS score = 4) or botulinum toxin injection less than 12 weeks old in the forearm or hand
  • History of degenarative neurological pathology or craniectomy
  • Deficient upper limb skin lesion preventing use of mucle stimulation
  • Skin lesion of the scalp preventing EEG placement
  • Participation in biomedical therapeutic research that may affect the recovery of the deficient hand during the study
  • Patient who has previously participated in a therapeutic study rTMS (excluding single shock) or a BCI
  • Patient who does not wish to be informed of a brain abnormality discovered accidentally on MRI
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • No intervention
    rTMS-free group

    Chronic stroke patients with motor deficit of upper limb

  • Experimental
    Contralesional Inhibitory stimulation of the M1 cortex.

    The probe will be placed on the healthy motor cortex at the Extensor Carpi Radialis " hotspot " level. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect

    Device: Repetitive transcranial magnetic stimulation (rTMS)

  • Experimental
    Ipsilesional excitatory stimulation of the M1 cortex.

    The probe will be placed on the injured motor cortex at the Extensor Carpi Radialis " hotspot " level. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect

    Device: Repetitive transcranial magnetic stimulation (rTMS)

  • Experimental
    Personalized exitatory stimulation according to structural connectivity.

    The probe will be placed at the stimulation site identified by control theory. Performed on 15 participants (5 participants per group) * Group A : chronic stroke with severe upper limb motor deficit (UE-FMA score ≤ 31) * Group B : chronic stroke with mild upper limb motor deficit (UE-FMA score \> 31) * Group C : chronic stroke with upper limb motor deficit with hemineglect

    Device: Repetitive transcranial magnetic stimulation (rTMS)

Interventions

  • DeviceRepetitive transcranial magnetic stimulation (rTMS)

    The repeated stimulations will be carried out using an eight-part probe detected by the infrared camera ("eight shaped tracked coil"), connected to a Rapid 2 stimulator (Magstim Company, Whitland, UK). The stimulation will be performed manually or with robotic assistance using TMS-Robot (Axilum Robotics, SCHILTIGHEIM, France)

06

What researchers measure

Primary outcomes

  1. Measuring primary BCI performance

    Accuracy was choosen, which correspond to the percentage of correct detection of mental tasks (either MI or rest) on all tasks performed during the session.

    Time frame: 6 weeks, 18 weeks

Secondary outcomes

  1. Measuring secondary BCI performance by using the sensitivity indicator " recall "

    Sensitivity is the proportion of correct IM task detections out of all real IM tasks

    Time frame: Up to 20 weeks

  2. Measuring secondary BCI performance by using the positive predictive value " precision "

    The positive predictive value is the proportion of correct MI detections out of all tasks detected by algorithm

    Time frame: Up to 20 weeks

  3. Measuring secondary BCI performance by using the Run-Wise Cross-Validation method

    To reduce the the intersessional variabilityy in accurnc, we use the Run-Wise Cross-Validation (RWCV CA) method will be used.

    Time frame: Up to 20 weeks

  4. Assessment of the motor function using the Fugl-Meyer upper limb motor subscale (UE-FMA)

    Rough assessment of dexterity during goal directed movements

    Time frame: Inclusion visit, 6 weeks

  5. Assessment of the motor function using Box and Block Test (BBT)

    Rough assessment of dexterity during goal directed movements

    Time frame: Up to 20 weeks

  6. Assessment of the motor function using the Grip and Pinch force

    Pure evaluation of the finger flexion force using dynamometer

    Time frame: Up to 20 weeks

  7. Evaluation of spasticity

    Will be assessed and monitored using the modified Ashworth scale (mAs score)

    Time frame: Inclusion visit, 6 weeks

  8. Hemineglet assessment by text reading test

    A text reading test in which the number of words correctly read in one minute and the percentage of words omitted will be counted

    Time frame: Up to 20 weeks

  9. Hemineglet assessment by line bissection test

    The measurement of the center deviation will be quantified

    Time frame: Up to 20 weeks

  10. Analysis of spectral power

    Measurement of the power of electrical signal produced by the brain depending on frequency

    Time frame: Up to 20 weeks

  11. Phase-Amplitude Coupling (PAC) analysis

    By analysing the phase-amplitude relationships of different frequency bands in the EEG signal

    Time frame: Up to 20 weeks

  12. Quantification of the functional connectivity (FC)

    To quantify this communication, we will use a correlation matrix constructed by calculating the coefficients of spectral coherence between all of EEG channels pairs

    Time frame: 2 minutes before starting rTMS stimulation

  13. Measurement of cortical excitability (Motor Evoked Potentials)

    Assessment of the amplitude of MEPs per single shock TMS and representes the therapeutic target of rTMS

    Time frame: Inclusion visit, 6 weeks, 18 weeks

07

Study locations

1 of 1 sites recruiting
  • Institut du Cerveau
    Paris, 75013, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 30, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2029
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06951035
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Apr 25, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jun 5, 2026

Study contacts

Paolo BARTOLOMEO, MD, INSERM DR2
Contact
paolo.bartolomeo@upmc.fr
+33 1 57 27 41 40

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion